{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:59:28Z","timestamp":1784959168316,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100017723","name":"Innovent Biologics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03419-w","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:44:43Z","timestamp":1769499883000},"page":"1274-1289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase\u00a02 Trial"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct05970978","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Qing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanying","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouxuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiwei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"issue":"19","key":"3419_CR1","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1001\/jama.2022.5270","volume":"327","author":"K Walter","year":"2022","unstructured":"Walter K. Psoriasis. JAMA. 2022;327(19):1936\u20131936.","journal-title":"JAMA"},{"issue":"19","key":"3419_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"key":"3419_CR3","doi-asserted-by":"publisher","unstructured":"Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin J Dermatol. 2023. https:\/\/doi.org\/10.35541\/cjd.20220839.","DOI":"10.35541\/cjd.20220839"},{"key":"3419_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117431","volume":"179","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhan W, Guo D, et al. GPR97 depletion aggravates imiquimod-induced psoriasis pathogenesis via amplifying IL-23\/IL-17 axis signal pathway. Biomed Pharmacother. 2024;179:117431.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"3419_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cytogfr.2015.07.005","volume":"26","author":"DM Floss","year":"2015","unstructured":"Floss DM, Schr\u00f6der J, Franke M, Scheller J. Insights into IL-23 biology: from structure to function. Cytokine Growth Factor Rev. 2015;26(5):569\u201378.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"3419_CR6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","volume":"13","author":"B Oppmann","year":"2000","unstructured":"Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715\u201325.","journal-title":"Immunity"},{"issue":"4","key":"3419_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/JD9.0000000000000244","volume":"5","author":"X Li","year":"2022","unstructured":"Li X, Zheng J, Pan WL, et al. Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 60-week results from a phase\u00a03 study. Int J Dermatol Venereol. 2022;5(4):181\u201390.","journal-title":"Int J Dermatol Venereol"},{"issue":"2","key":"3419_CR8","first-page":"166","volume":"12","author":"X Zhu","year":"2013","unstructured":"Zhu X, Zheng M, Song M, et al. Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase\u00a03 clinical trial (LOTUS). J Drugs Dermatol. 2013;12(2):166\u201374.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"3419_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jdv.13746","volume":"31","author":"L Cai","year":"2017","unstructured":"Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase\u00a03, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017;31(1):89\u201395.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"3419_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1684\/ejd.2020.3878","volume":"30","author":"H Huang","year":"2020","unstructured":"Huang H, Cai ML, Hong XJ, et al. Real-world data on the use of secukinumab as treatment for moderate-to-severe psoriasis in Chinese patients. Eur J Dermatol. 2020;30(5):554\u201360.","journal-title":"Eur J Dermatol"},{"issue":"9","key":"3419_CR11","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","volume":"160","author":"K Eyerich","year":"2024","unstructured":"Eyerich K, Asadullah K, Pinter A, et al. Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial. JAMA Dermatol. 2024;160(9):953\u201363.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3419_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.18143","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. Br J Dermatol. 2020;182(2):304\u201315.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"3419_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/21556660.2019.1658298","volume":"8","author":"R Baiano","year":"2019","unstructured":"Baiano R, Staskon F, Miller R. Psoriasis patients utilizing secukinumab, ixekizumab, or brodalumab\u2014comparisons to prior biologic medication adherence levels, reasons for switching, and reported changes in disease symptoms. J Drug Assess. 2019;8(Suppl 1):3.","journal-title":"J Drug Assess"},{"issue":"11","key":"3419_CR14","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1001\/archdermatol.2011.309","volume":"147","author":"ML Schaarschmidt","year":"2011","unstructured":"Schaarschmidt ML, Schmieder A, Umar N, et al. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol. 2011;147(11):1285\u201394.","journal-title":"Arch Dermatol"},{"issue":"89","key":"3419_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107008","volume":"1","author":"L Li","year":"2020","unstructured":"Li L, Wu Z, Wu M, et al. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis. Int Immunopharmacol. 2020;1(89):107008.","journal-title":"Int Immunopharmacol"},{"issue":"7","key":"3419_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/13543784.2023.2230122","volume":"32","author":"J He","year":"2023","unstructured":"He J, Du W, Yang H, et al. Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase\u00a01 study. Expert Opin Investig Drugs. 2023;32(7):669\u201375.","journal-title":"Expert Opin Investig Drugs"},{"issue":"Supplement_3","key":"3419_CR17","first-page":"46","volume":"191","author":"Y Shi","year":"2024","unstructured":"Shi Y, Qin L, Li Y, et al. Efficacy and safety of picankibart in moderate-to-severe plaque psoriasis: a randomized, double-blind, phase\u00a03 CLEAR-1 trial. Br J Dermatol. 2024;191(Supplement_3):46\u20137.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3419_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12248-021-00649-y","volume":"24","author":"H Myler","year":"2021","unstructured":"Myler H, Pedras-Vasconcelos J, Phillips K, et al. Anti-drug antibody validation testing and reporting harmonization. AAPS J. 2021;24(1):4.","journal-title":"AAPS J"},{"key":"3419_CR19","unstructured":"Food and Drug Administration. Immunogenicity testing of therapeutic protein products\u2014developing and validating assays for anti-drug antibody detection. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug. Accessed February 2019"},{"issue":"2","key":"3419_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s13555-024-01328-4","volume":"15","author":"RB Warren","year":"2025","unstructured":"Warren RB, Pavlovsky L, Costanzo A, et al. Efficacy and safety of risankizumab in patients with psoriasis showing suboptimal response to secukinumab or ixekizumab: results from a phase\u00a03b, open-label, single-arm (aIMM) study. Dermatol Ther (Heidelb). 2025;15(2):477\u201381.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"3419_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase\u00a0III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"10198","key":"3419_CR22","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase\u00a03 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"issue":"6","key":"3419_CR23","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/bjd.18484","volume":"182","author":"AB Kimball","year":"2020","unstructured":"Kimball AB, Papp KA, Reich K, et al. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase\u00a0III studies. Br J Dermatol. 2020;182(6):1359\u201368.","journal-title":"Br J Dermatol"},{"issue":"10148","key":"3419_CR24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase\u00a03 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"9","key":"3419_CR25","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","volume":"5","author":"K Papp","year":"2023","unstructured":"Papp K, Warren RB, Green L, et al. Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase\u00a03, multicentre, randomised, double-blind study. Lancet Rheumatol. 2023;5(9):e542\u201352.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"3419_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/bjd.12039","volume":"168","author":"RJ Thorneloe","year":"2013","unstructured":"Thorneloe RJ, Bundy C, Griffiths CEM, Ashcroft DM, Cordingley L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20\u201331.","journal-title":"Br J Dermatol"},{"issue":"4","key":"3419_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40257-022-00679-y","volume":"23","author":"M Masson Regnault","year":"2022","unstructured":"Masson Regnault M, Shourick J, Jendoubi F, Tauber M, Paul C. Time to relapse after discontinuing systemic treatment for psoriasis: a systematic review. Am J Clin Dermatol. 2022;23(4):433\u201347.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"3419_CR28","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1016\/j.jid.2020.03.504","volume":"140","author":"S Bell","year":"2020","unstructured":"Bell S, Domire J, Merola J, Gottlieb A, Gondo G. The impact of psoriasis and its associated comorbidities on quality of life: results from the National Psoriasis Foundation annual survey. J Invest Dermatol. 2020;140(7):S67.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"3419_CR29","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/bjd.20657","volume":"185","author":"GC Gondo","year":"2021","unstructured":"Gondo GC, Merola JF, Bell SJ, Blauvelt A. Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey. Br J Dermatol. 2021;185(6):1264\u20135.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3419_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase\u00a0III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","journal-title":"Br J Dermatol"},{"issue":"10091","key":"3419_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE\u00a02): results from two randomised controlled, phase\u00a03 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"9","key":"3419_CR32","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/1346-8138.14504","volume":"45","author":"M Ohtsuki","year":"2018","unstructured":"Ohtsuki M, Kubo H, Morishima H, Goto R, Zheng R, Nakagawa H. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: efficacy and safety results from a phase\u00a03, randomized, double-blind, placebo-controlled study. J Dermatol. 2018;45(9):1053\u201362.","journal-title":"J Dermatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03419-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03419-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03419-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:30:14Z","timestamp":1773822614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03419-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3419"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03419-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rouxuan Ye, Yuanfang Ren, and Haiwei Du are employees of Innovent Biologics. Qing Yang, Bin Yang, Heng Gu, Liming Wu, Lanying Qin, Lihua Wang, Yumei Li, Lixiong Gu, Zhu Shen, Siping Zhang, Jianyun Lu, Yuling Shi, Xiaohua Tao, Yong Cui, Shifa Zhang, Hong Ren, Linfeng Li, Xiaoyong Man, Hui Chen, Rong Xiao, Ziliang Yang, and Furen Zhang have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All patients provided written informed consent before the initiation of any study-related procedures. The trial obtained the ethics committee approval from the Affiliated Dermatology Hospital of Shandong First Medical University (20230705YWLC001) on July 5, 2023. This trial was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonization for Good Clinical Practice Guidelines, and applicable local laws and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}